In this lecture we are going to discuss pharmacology of antihistamines. But before we do that, let's first talk about what is histamine and what does it do. So histamine is a small molecule produced in our bodies by decarboxylation of the amino acid histidine. It is widely distributed throughout all tissues but is particularly concentrated in the skin, lungs and gastrointestinal tract. Most of histamine is generated and stored within granules in mast cells located within tissues basophils and eosinophils circulating in the blood and enterochromophin-like cells located in the stomach lining.
Now there are three major conditions that trigger the release of histamine. First, allergic reaction. So when an allergy prone individual for the first time comes into contact with allergen such as ragweed pollen, their B cells will become activated and will form plasma cells that produce large amounts of Ragweed immunoglobulin E antibodies.
These antibodies, abbreviated as IgE, firmly attach themselves to mast cells. Now when that same person comes into contact with Ragweed pollen again, the binding of allergen to IgE antibodies will trigger activation of the mast cell, which will then release granules rich in histamine. Now let's move on to the second condition which triggers histamine release, that is tissue injury.
So when tissue injury occurs, the damaged mast cells release chemical mediators, among them histamine, which affect blood vessels and nerves in the damaged area. Finally, the third major stimulus which triggers histamine release can come from drugs and foreign chemicals. Compounds found in venoms, antibiotic bases, dyes and alkaloids such as morphine are a few examples that can directly displace histamine from the granule stores. So now what does histamine do following its release? Well histamine exerts its effects by binding to various types of histamine receptors found on many different cells throughout the body.
To date four types of histamine receptors have been identified and these are H1, H2, H3 and H4. That being said, in this lecture we are going to focus only on the first two types, as they are the main targets of clinically useful drugs. So the first type H1 receptors are expressed primarily on vascular endothelial cells, smooth muscle cells, as well as in the brain and on peripheral nerve endings. These receptors mediate mainly inflammatory and allergic reactions. So when histamine binds to vascular endothelial receptors, it causes blood vessels to dilate, thus making them more permeable, ultimately leading to redness and edema.
Now when histamine binds to smooth muscle receptors, particularly the ones located in bronchioles, it causes bronchoconstriction. Histamine also acts as a neurotransmitter within the central nervous system. Histamine binding to the H1 receptors in the brain promotes among other things wakefulness, and appetite suppression. Lastly, histamine-mediated stimulation of peripheral nerve endings leads to pain and itching sensations.
Now let's move on to the histamine type 2 receptors. So, H2 receptors are expressed mainly on gastric parietal cells. When histamine binds to these receptors, it causes increased gastric acid secretion. Now let's switch gears and let's talk about drugs that block the action of histamine.
starting with H1 receptor blockers, classically referred to as antihistamines. So the H1 receptor blockers can be divided into the older or first generation agents and the newer or second generation agents. These agents act as inverse agonists, meaning they bind to H1 receptor on a target tissue and stabilize its inactive conformation.
This leads to inhibition of histaminic actions and gradual relief of allergy-related symptoms such as inflammation, itching, runny nose and sneezing. Now the general structure of the first generation H1 antihistamines consists of two aromatic rings connected to a substituted ethylamine group. Due to this lipophilic structure, first generation H1 antihistamines can cross the blood-brain barrier and thus cause sedation. and potentially impair cognitive function.
Additionally, first-generation agents have relatively poor H1 receptor selectivity and as a result, they are capable of occupying other receptors such as cholinergic, alpha-adrenergic and serotonin receptors. This leads to a number of side effects. For example, blockade of cholinergic receptors may cause dry mouth, blurred vision and urinary retention.
Blockade of alpha-adrenergic receptors may cause hypotension and reflex tachycardia. And lastly, blockade of serotonin receptors may cause increased appetite. On the positive side, blockade of central histamine and acetylcholine receptors seems to be responsible for anti-emetic and anti-nausea effects. Examples of first-generation atron antihistamine include bromphenyramine, chlorphenyramine, clamastine, cyproheptadine, diphenhydramine, doxylamine, hydroxyzine, meclizine, and promethazine.
Although all of these drugs are useful in relieving allergy symptoms, some of them are often used for other therapeutic indications. For example, diphenhydramine and doxylamine are often used in the treatment of insomnia. while meclizine and promethazine are more often used in the treatment of nausea and vomiting related to certain conditions such as motion sickness.
Now let's move on to the second generation H1 antihistamines. So unlike the first generation, second generation agents have bulkier and less lipophilic structure. Therefore they do not cross the blood-brain barrier as readily. Furthermore they are much more selective for the peripheral H1 receptors involved in allergies as opposed to the H1 receptors in the central nervous system.
As a result, second generation drugs provide the same allergy symptom relief but with less side effects such as sedation. Examples of second generation H1 antihistamine include citerizine, desloratidine, vexofenadine, levocitirizine and loratidine. Additionally, we can include in this group drugs that have both antihistamine and mast cell stabilizing effects, namely azelastine and olopatidine that are available in ophthalmic and nasal formulations as well as ketorafen which is currently available in ophthalmic formulation only and as a side note here keep in mind that in some medical literature ketorafen is classified as a first generation antihistamine now before we end let's quickly discuss histamine type 2 receptor blockers also called h2 antagonists so in order to understand how these drugs work, first we need to take a closer look at their primary target, that is acid-producing parietal cells of the stomach.
So parietal cell has three types of receptors which control acid production. That is acetylcholine receptor, gastrin receptor and histamine H2 type receptor. Now parasympathetic vagus nerve that innervates the GI tract releases acetylcholine which acts on acetylcholine receptor to increase intracellular calcium. Next, gastrin, which is a hormone produced by G cells located in the pyloric glands, acts on gastrin receptor to, just like acetylcholine, increase intracellular calcium.
Additionally, gastrin stimulates nearby enterochromaffin-like cells to synthesize and secrete histamine. Finally, histamine secreted from enterochromaffin-like cells acts on H2 receptor to activate adenyl cyclase leading to increase of intracellular cyclic AMP levels. Now this increase in intracellular cAMP and calcium results in activation of protein kinases which in turn stimulate hydrogen potassium ATPase. This so-called gastric proton pump secretes hydrogen ions into the lumen of stomach in exchange for potassium.
So H2 receptor antagonists selectively block H2 receptor sites thus effectively reduce the secretion of gastric acid. This makes them useful in treatment of gastric ulcers and gastroesophageal reflux disease. Examples of H2 receptor antagonists include simethidine, famotidine, nizatidine and ranitidine. In general, these drugs are well tolerated so adverse effects are few and mild with the most common being headache.
Out of the four, cimetidine is the most likely to cause drug-drug interactions and side effects, some of which may include gynecomastia and galactorrhea due to its anti-androgenic and prolactin stimulating effects. And with that I wanted to thank you for watching, I hope you enjoyed this video and as always stay tuned for more.